UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (26) 26
life sciences & biomedicine (26) 26
science & technology (26) 26
male (24) 24
female (23) 23
middle aged (23) 23
abridged index medicus (19) 19
aged (18) 18
cardiac & cardiovascular systems (17) 17
cardiovascular system & cardiology (17) 17
treatment outcome (16) 16
myocardial infarction (14) 14
secondary prevention (14) 14
myocardial infarction - drug therapy (13) 13
double-blind method (12) 12
heart attacks (12) 12
risk factors (10) 10
general & internal medicine (9) 9
heart attack (9) 9
medicine, general & internal (9) 9
patients (9) 9
stroke (9) 9
analysis (8) 8
cardiovascular diseases (8) 8
care and treatment (8) 8
dosage and administration (8) 8
hemorrhage - chemically induced (8) 8
myocardial infarction - diagnosis (8) 8
cardiology (7) 7
cardiovascular disease (7) 7
kaplan-meier estimate (7) 7
myocardial infarction - mortality (7) 7
prevention (7) 7
ticagrelor (7) 7
cardiovascular diseases - mortality (6) 6
cerebral infarction (6) 6
diabetes mellitus (6) 6
life sciences (6) 6
pyridines - therapeutic use (6) 6
risk (6) 6
stroke - prevention & control (6) 6
[sdv]life sciences [q-bio] (5) 5
adenosine - analogs & derivatives (5) 5
atherosclerosis (5) 5
clinical medicine (5) 5
clinical trials (5) 5
coronary heart disease (5) 5
drug administration schedule (5) 5
drug therapy (5) 5
electrocardiography (5) 5
ischemia (5) 5
klinisk medicin (5) 5
lactones - therapeutic use (5) 5
myocardial infarction - therapy (5) 5
platelet aggregation inhibitors - adverse effects (5) 5
platelet aggregation inhibitors - therapeutic use (5) 5
time factors (5) 5
transluminal angioplasty (5) 5
acute coronary syndrome (4) 4
adenosine - administration & dosage (4) 4
antiplatelet therapy (4) 4
aspirin (4) 4
bleeding (4) 4
cardiac patients (4) 4
cardiovascular diseases - prevention & control (4) 4
coronary angiography (4) 4
coronary vessels (4) 4
diabetes (4) 4
follow-up studies (4) 4
mortality (4) 4
myocardial infarction - prevention & control (4) 4
percutaneous coronary intervention (4) 4
peripheral vascular disease (4) 4
purinergic p2y receptor antagonists - administration & dosage (4) 4
pyridines - adverse effects (4) 4
recurrence (4) 4
safety (4) 4
secondary prevention - methods (4) 4
[sdv.mhep]life sciences [q-bio]/human health and pathology (3) 3
acute coronary syndrome - drug therapy (3) 3
acute coronary syndromes (3) 3
adenosine - adverse effects (3) 3
angioplasty, balloon, coronary (3) 3
arteriosclerosis (3) 3
aspirin - administration & dosage (3) 3
atrial fibrillation (3) 3
cardiac and cardiovascular systems (3) 3
clinical outcomes (3) 3
complications and side effects (3) 3
coronary artery disease (3) 3
death (3) 3
diabetes mellitus, type 2 - complications (3) 3
diabetes mellitus, type 2 - drug therapy (3) 3
disease prevention (3) 3
drug approval (3) 3
drug therapy, combination (3) 3
health risk assessment (3) 3
heart (3) 3
hospitalization (3) 3
human health and pathology (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England journal of medicine, ISSN 1533-4406, 04/2012, Volume 366, Issue 15, pp. 1404 - 1413
Patients with atherosclerotic vascular disease were randomly assigned to receive the thrombin antagonist vorapaxar or placebo. Vorapaxar reduced the rate of... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Male | Risk | Secondary Prevention | Pyridines - adverse effects | Cardiovascular Diseases - mortality | Female | Platelet Aggregation Inhibitors - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | Pyridines - therapeutic use | Double-Blind Method | Hemorrhage - epidemiology | Receptor, PAR-1 - antagonists & inhibitors | Kaplan-Meier Estimate | Peripheral Arterial Disease - drug therapy | Stroke - drug therapy | Lactones - adverse effects | Lactones - therapeutic use | Retreatment | Myocardial Infarction - drug therapy | Brain Ischemia - drug therapy | Intracranial Hemorrhages - chemically induced | Intracranial Hemorrhages - epidemiology | Aged | Hemorrhage - chemically induced | Prevention | Drugs | Aggregation | Dose-response relationship (Biochemistry) | Atheroembolism | Blood platelets | Atherosclerosis | Product/Service Evaluations | Dosage and administration | Drug therapy | Myocardial infarction | Cerebral infarction | Stroke | Aspirin | Heart attacks | Proteinase-activated receptor 1 | Thrombin | Hemorrhage | Patients | Bleeding | Disease prevention | Ischemia | Arteriosclerosis | Death | Cardiovascular diseases | Health risk assessment | Index Medicus | Abridged Index Medicus | Computer Science | Medical Imaging
Journal Article
JAMA : the journal of the American Medical Association, ISSN 0098-7484, 04/2016, Volume 315, Issue 15, pp. 1591 - 1599
IMPORTANCE: p38 Mitogen-activated protein kinase (MAPK)–stimulated inflammation is implicated in atherogenesis, plaque destabilization, and maladaptive... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Recurrence | Myocardial Infarction - mortality | Humans | Middle Aged | Male | Secondary Prevention | Cyclopropanes - adverse effects | Protein Kinase Inhibitors - adverse effects | Cyclopropanes - therapeutic use | Pyridines - adverse effects | Treatment Failure | Female | C-Reactive Protein - analysis | Myocardial Infarction - enzymology | Pyridines - therapeutic use | Double-Blind Method | Drug Administration Schedule | Myocardial Ischemia - prevention & control | Hospitalization | Myocardial Revascularization | Algorithms | Myocardial Infarction - drug therapy | Protein Kinase Inhibitors - therapeutic use | p38 Mitogen-Activated Protein Kinases - antagonists & inhibitors | Aged | Myocardial Ischemia - surgery | Clinical trials | Care and treatment | Usage | Dosage and administration | Extracellular signal-regulated kinases | Heart attack | Patient safety | Inhibitor drugs | Heart attacks | Clinical outcomes | Index Medicus | Abridged Index Medicus | Pyridines/adverse effects/therapeutic use | Cyclopropanes/adverse effects/therapeutic use | C-Reactive Protein/analysis | Klinisk medicin | Clinical Medicine | p38 Mitogen-Activated Protein Kinases/antagonists & inhibitors | Myocardial Ischemia/prevention & control/surgery | Protein Kinase Inhibitors/adverse effects/therapeutic use | Myocardial Infarction/drug therapy/enzymology/mortality
Journal Article
Journal of the American Heart Association, ISSN 2047-9980, 03/2015, Volume 4, Issue 3, pp. e001505 - e001505
Background-Vorapaxar is a protease-activated receptor-1 antagonist approved by the U.S. Food and Drug Administration (FDA) for the reduction of thrombotic... 
atherosclerosis | vorapaxar | peripheral arterial disease | secondary prevention | antiplatelet therapy | myocardial infarction | Cardiac & Cardiovascular Systems | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Index Medicus
Journal Article
The New England journal of medicine, ISSN 1533-4406, 06/2015, Volume 372, Issue 25, pp. 2387 - 2397
Journal Article
Circulation (New York, N.Y.), ISSN 0009-7322, 2016, Volume 134, Issue 24, pp. 1918 - 1930
Journal Article
European heart journal. Cardiovascular pharmacotherapy, ISSN 2055-6837, 06/2019, Volume 5, Issue 4, pp. 200 - 206
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 2016, Volume 67, Issue 13, pp. 2146 - 2146
Methods Pts with MI 1-3 years prior from PEGASUS-TIMI 54 were stratified by MVD and analzyed for the primary efficacy endpoint (PEP; CV death, MI, Stroke),... 
Cardiovascular | Internal Medicine | Prevention | Coronary heart disease | Care and treatment | Heart attacks
Journal Article
Circulation (New York, N.Y.), ISSN 0009-7322, 09/2016, Volume 134, Issue 12, pp. 861 - 871
Journal Article
The New England journal of medicine, ISSN 1533-4406, 10/2013, Volume 369, Issue 14, pp. 1317 - 1326
Saxagliptin, a new oral antihyperglycemic drug in the DPP-4 inhibitor class, had no effect on the risk of cardiovascular events in patients with type 2... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Humans | Middle Aged | Hospitalization - statistics & numerical data | Male | Adamantane - therapeutic use | Aged, 80 and over | Cardiovascular Diseases - epidemiology | Cardiovascular Diseases - mortality | Female | Hypoglycemia - chemically induced | Heart Failure - epidemiology | Diabetes Mellitus, Type 2 - complications | Adamantane - adverse effects | Adamantane - analogs & derivatives | Hypoglycemic Agents - therapeutic use | Cardiovascular Diseases - etiology | Dipeptides - therapeutic use | Double-Blind Method | Pancreatitis - epidemiology | Dipeptides - adverse effects | Kaplan-Meier Estimate | Pancreatitis - chemically induced | Aged | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Type 2 diabetes | Complications and side effects | Patient outcomes | Dosage and administration | Drug therapy | Heart diseases | Risk factors | Saxagliptin | Myocardial infarction | Cerebral infarction | Heart attacks | Peptidase | Diabetes mellitus | Pancreatitis | Cardiovascular disease | Angina | Patients | Heart rate | Ischemia | Diabetes | Cardiovascular diseases | Diabetes mellitus (non-insulin dependent) | Index Medicus | Abridged Index Medicus
Journal Article